Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tapering Abatacept or Tocilizumab in Rheumatoid Arthritis in Remission. An Evaluation of Disease Activity, Relapse Risk, Structural Progression and the Economic Impact of a Tapering Strategy

NCT01557374 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT01557374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01557374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tapering Abatacept or Tocilizumab in Rheumatoid Arthritis in Remission. An Evaluation of Disease Activity, Relapse Risk, Structural Progression and the Economic Impact of a Tapering Strategy
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2012
Completion date
November 8, 2019
Enrollment
232 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis